MediciNova, Inc., the biopharmaceutical company developing ibudilast (MN-166), announced that this investigational medication for progressive forms of MS has received Fast Track designation from the United States Food and Drug Administration (FDA). This designation is intended for drugs under development for treating serious diseases and with the potential to address unmet medical needs for such diseases.